It is possible that a strong rotation back into Biotech could more than offset the
continued shortfalls of our stumbling,bumbling CEO Later and Less Anderson.
Investors are still waiting for the promised Q2 start of the SO Phase III trial.The
start will be late but how short of its promise
When does Deerfield run out of patience and punt Later and Less,sell out to Teva and
move their chips to a better bet.